Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients
By Jonathan Scheiner, Research Assistant
A study published in The New England Journal of Medicine (2018) has shown that TAVR, a conventional procedure for patients at high risk for death from complications associated with undergoing open heart surgery is an equally effective method for treating aortic narrowing (or stenosis) in low-risk patients. Dr. George Petrossian and Dr. Newell Robinson, Co-Directors of the John Brancaccio Heart Valve Center at St. Francis Hospital, have not only pioneered the initial usage of TAVR but have also now contributed significantly to this international, multicenter low-risk-patient study. One month after the procedure, low-risk TAVR patients were found to have lower rates of stroke, bleeding complications, and especially atrial fibrillation when compared to traditional aortic valve replacement surgery, with TAVR and surgery being equally effective in aortic valve improvement over one and two years. Further investigation may strengthen TAVR as an overall favorable method of treating patients with severe aortic narrowing, and Dr. Petrossian, Dr. Robinson, and St. Francis Hospital will continue to be a leading force in TAVR procedures and research.